Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Natera Inc. Common Stock (NTRA) vs Zscaler Inc (ZS) Price & Performance

Natera Inc. Common StockTrade
Zscaler IncTrade

Price performance (Past 24H)

Key statistics

Natera Inc. Common Stock vs Zscaler Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Zscaler Inc trades at $218.07 (market cap $36.81B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Zscaler Inc for 41 Days on average.

NTRAZS
Market Cap
$57.03B$36.81B
Volume
1,131,1572,661,492
Sector
HealthTechnology
52-Week High
$425.64$336.27
52-Week Low
$179.42$118.05
Typical Hold Time
0 Days41 Days
Enterprise Value
$56.18B$35.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Natera Inc. Common Stock

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

Zscaler Inc

Zscaler (ZS) trades at $220.79, down 2.21% on the day, amid mixed signals. The stock shows strong technical momentum with bullish moving averages, but RSI suggests potential overbought conditions. Fundamentally, revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net income margin of -1.88%. Recent news includes executive changes and an upcoming Investor Day on October 6, 2026.

The outlook is cautiously optimistic. Analyst consensus is strongly bullish with a $222.83 price target, but risks include persistent losses, competitive pressures, and insider selling. Upside hinges on AI-driven bookings growth and execution stability post-CRO transition. Investors should weigh high valuation multiples against the company's growth trajectory and market position in cybersecurity.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NTRA
100% Buy0% Sell
Avg holding period · 0 Days
ZS
1% Buy99% Sell
Avg holding period · 41 Days

Top news

Latest headlines on both assets

About Natera Inc. Common Stock

Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.

Read more on NTRA →

About Zscaler Inc

Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.

Read more on ZS →